Teratogenicity assessment of new antiviral drugs using 3D morphogenesis models
Teratogenicity assessment of new antiviral drugs using 3D morphogenesis models
批准号:
10741474
负责人:
YUSUKE MARIKAWA
金额:
$15.65万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-08-10 至 2025-07-31
关键词:
2019-nCoV3-DimensionalAdoptedAdultAdverse effectsAffectAnimalsAntiviral AgentsBrainCOVID-19COVID-19 pandemicCellsChemicalsClinical TrialsCongenital AbnormalityDNA-Directed RNA PolymeraseDataDevelopmentDrug usageEmbryoEmbryonic DevelopmentEmbryonic StructuresEventExclusionExposure toFDA Emergency Use AuthorizationGene ExpressionGenesGrantHeartHumanImmuneImpairmentIn VitroIncidenceInvestigationLinkMarketingMetabolicMethodsMitochondrial RNAModelingMolecularMolecular AnalysisMolecular Mechanisms of ActionMorphogenesisMorphologyMusPatientsPatternPaxlovidPersonsPharmaceutical PreparationsPhosphorylationPhysiciansPlasmaPregnancyResearch PersonnelRiskSomitesSpontaneous abortionStructureTeratogenic effectsTeratogensTestingTherapeuticToxicokineticsToxicologyVariantViralViruschemical propertychild bearingdesignembryo cultureexperimental studygrasphuman pluripotent stem cellhuman stem cellsin vivoinnovationinventionmolnupiravirnovelpharmacologicpregnantremdesivirstem cellsthree dimensional cell culturetooltranscriptome sequencingtranscriptomicswhole genome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Proposal Abstract
Various drugs are known to be teratogenic, causing miscarriages or birth defects, when used during
pregnancy. However, teratogenicity is unclear for many other drugs, particularly those that were recently
marketed. Because of the ongoing COVID-19 pandemic/endemic, many investigators are developing new
antiviral drugs against SARS-CoV-2. Currently, three antivirals are approved or granted the emergency use
authorization by the FDA, namely remdesivir, molnupiravir, and Paxlovid. Yet studies on their teratogenicity are
scarce. As COVID-19 still persists with the emergence of immune escape variants, many people, including
those of childbearing potential, may require antiviral treatment. For physicians to provide proper advice for
their patients, the teratogenicity of the antivirals should be studied sufficiently. Previously, we invented the
mouse and human stem cell-based 3D morphogenesis models, which recapitulate the key features of early
embryogenesis in vitro and can serve as effective tools to sensitively and specifically detect various teratogenic
chemicals. Our Preliminary Studies using these morphogenesis models suggest that the anti-COVID-19
drugs, particularly remdesivir and molnupiravir, impair embryogenesis at the concentrations close to their
therapeutic plasma levels in human. These observations necessitate further investigations into the teratogenic
potential of the antivirals, as proposed in this application. Specifically, we will (1) characterize the molecular
impact of the new antivirals on the morphogenesis models, (2) explore the possible teratogenic mechanisms of
the new antivirals, and (3) examine the teratogenic effects of the new antivirals with the mouse whole embryo
culture. The proposed experiments should yield valuable information pertinent to their teratogenic potential,
such as the concentration-effect relationship and molecular mechanisms of actions, and help in the design and
interpretation of animal- and human-based studies in an effective manner.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Human pluripotent stem cell-based assessment of dolutegravir teratogenicity
-
批准号:10231131
-
项目类别:
-
资助金额:$7.8万
-
财政年份:2020
-
负责人:YUSUKE MARIKAWA
-
依托单位:
Human pluripotent stem cell-based assessment of dolutegravir teratogenicity
-
批准号:10043778
-
项目类别:
-
资助金额:$7.78万
-
财政年份:2020
-
负责人:YUSUKE MARIKAWA
-
依托单位:
Regeneration of meiotic spindle during oocyte vitrification
-
批准号:8242474
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2012
-
负责人:YUSUKE MARIKAWA
-
依托单位:
Regeneration of meiotic spindle during oocyte vitrification
-
批准号:8518432
-
项目类别:
-
资助金额:$7.12万
-
财政年份:2012
-
负责人:YUSUKE MARIKAWA
-
依托单位:
MOLECULAR NATURE OF PLURIPOTENT STEM CELLS
-
批准号:6972106
-
项目类别:
-
资助金额:$3.59万
-
财政年份:2004
-
负责人:YUSUKE MARIKAWA
-
依托单位:
Body Plan Formation in Early Mouse Embryo
-
批准号:6638010
-
项目类别:
-
资助金额:$18.4万
-
财政年份:2001
-
负责人:YUSUKE MARIKAWA
-
依托单位:
Body Plan Formation in Early Mouse Embryo
-
批准号:6744094
-
项目类别:
-
资助金额:$18.4万
-
财政年份:2001
-
负责人:YUSUKE MARIKAWA
-
依托单位:
Body Plan Formation in Early Mouse Embryo
-
批准号:6536304
-
项目类别:
-
资助金额:$17.79万
-
财政年份:2001
-
负责人:YUSUKE MARIKAWA
-
依托单位:
Body Plan Formation in Early Mouse Embryo
-
批准号:6316426
-
项目类别:
-
资助金额:$22.57万
-
财政年份:2001
-
负责人:YUSUKE MARIKAWA
-
依托单位:
海外基金